Innoviva, Inc. (HVE.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
At close: 09:50PM CEST
| Previous close | 14.90 |
| Open | 14.70 |
| Bid | 14.70 x 33200 |
| Ask | 14.90 x 32300 |
| Day's range | 14.70 - 14.70 |
| 52-week range | 11.00 - 15.40 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 925.193M |
| Beta (5Y monthly) | 0.58 |
| PE ratio (TTM) | 7.03 |
| EPS (TTM) | 2.09 |
| Earnings date | 31 Jul 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 08 Sept 2015 |
| 1y target est | N/A |
Simply Wall St.Calculating The Fair Value Of Innoviva, Inc. (NASDAQ:INVA)
Key Insights Innoviva's estimated fair value is US$19.59 based on 2 Stage Free Cash Flow to Equity Current share price...
Business WireInnoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
BURLINGAME, Calif., June 03, 2024--Innoviva, Inc. (Nasdaq: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL
- GuruFocus.com
Innoviva Inc (INVA) Reports First Quarter 2024 Earnings: A Detailed Analysis
Strong Performance with Significant Growth in Net Product Revenue
© 2024 Yahoo. All rights reserved.